Search Results

The AggreGuide A-100 ADP Assay is used with the AggreGuide A-100 instrument in non-CLIA waived physician's office or clinical laboratory for the detection of platelet dysfunction in patients age 22 or older receiving P2Y 12 antiplatelet drugs, prasugrel and ticagrelor, using 3.2% sodium citrated whole blood. The AggreGuide A-100 ADP Assay is a semi-quantitative assay. The level of platelet aggregation is determined by the platelet activity index (PAI) where values < 4.7 PAI suggest that platelet dysfunction is due to the presence of P2Y 12 antiplatelet drugs, prasugrel and ticagrelor. The test results should be interpreted in conjunction with all laboratory data available to the clinician.

The AggreGuide A-100 ADP Assay is an individual use, disposable assay cartridge for use with the AggreGuide A-100 instrument. The cartridge contains preloaded freeze dried agonist. The level of platelet aggregation induced by the adenosine diphosphate (ADP) agonist in a sample of whole blood is detected within the cartridge. The amount of platelet aggregation is measured by detecting and quantifying the laser light scattering caused by platelet aggregates. P2Y12 inhibitor drugs e.g. clopidogrel, and ticagrelor are known to inhibit the level of platelet aggregation, causing platelet dysfunction.

Here's a breakdown of the acceptance criteria and the study proving the device meets them, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

Note: The document only explicitly states numerical acceptance criteria for sensitivity. Specificity is provided as a reported value, implying it met an internal or expected threshold, though the exact numerical acceptance criterion for specificity isn't listed.

2. Sample Size Used for the Test Set and Data Provenance

The sample sizes for the sensitivity analysis (test set) are:

• Prasugrel: 43 patients for both Post-Loading (24 hours) and Post-Maintenance (7 days).
• Ticagrelor: 85 patients for Post-Loading (3-6 hours) and 143 patients for Post-Maintenance (7 days).

The document does not explicitly state the country of origin of the data or whether the study was retrospective or prospective. However, the study is described as "clinical testing" and evaluated against a "clinical truth data set comprising off-therapy (baseline) versus on-therapy with P2Y12 inhibitor medications. On-therapy clinical truth utilized high potency P2Y12 medications at a time of full-effect," which suggests a prospective clinical study design.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

The document does not specify the number of experts used to establish the ground truth or their qualifications. It simply refers to a "clinical truth data set."

4. Adjudication Method for the Test Set

The document does not describe any adjudication method used for establishing the ground truth of the test set.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not conducted. The study evaluated the standalone performance of the AggreGuide A-100 ADP Assay and compared its performance (sensitivity values) against another device (VerifyNow) on the same clinical truth data set, but not in the context of human reader improvement with and without AI assistance.

6. Standalone Performance (Algorithm Only Without Human-in-the-Loop Performance)

Yes, a standalone performance study was done. The reported sensitivity and specificity values are for the AggreGuide A-100 ADP Assay as a diagnostic device, without human intervention in the interpretation of the primary PAI result. The document says, "The level of platelet aggregation is determined by the platelet activity index (PAI) where values < 4.7 PAI suggest that platelet dysfunction..." This indicates the algorithm provides the direct output, which is then used for interpretation.

7. Type of Ground Truth Used

The ground truth used was clinical truth data. Specifically, it was established by comparing "off-therapy (baseline) versus on-therapy with P2Y12 inhibitor medications." The "on-therapy clinical truth utilized high potency P2Y12 medications at a time of full-effect." This implies a reference standard based on the known physiological state of the patient (presence or absence of platelet dysfunction due to specific P2Y12 inhibitors).

8. Sample Size for the Training Set

The document does not provide information regarding the sample size for the training set. It focuses solely on the performance testing carried out.

9. How the Ground Truth for the Training Set Was Established

Since the document does not provide information on a training set, it also does not describe how the ground truth for any training set would have been established. The provided data relates to clinical performance testing, implying a pre-defined or externally validated cut-off point. It states, "Cut Off Point is confirmed by ROC Decision Threshold / J-statistic (Youden) analysis of the clinical truth data set," suggesting the cut-off was determined using the available clinical truth data, rather than being established pre-emptively on a separate training set.

Ask a specific question about this device